In this indication, antibodies to HERV‐K (HML‐2) Env declined within a year after resection of the primary tumor or chemotherapy, and their retention after chemotherapy was associated with worse prognosis and the presence of residual primary tumor cells or metastases.20, 24. This evidence concerns the gene CLEC10A and neoplasm.